Name: ASTRAZENECA PLC-SPONS ADR (AZN) Stock
Brand: ASTRAZENECA PLC-SPONS ADR
Rating: 8 (3 reviews)

AZN Latest News, Press Relases and Analysis

All

Press Releases

5 hours ago - By: Chartmill

AstraZeneca PLC-SPONS ADR (NASDAQ:AZN) Passes Key Quality Investing Screen for Long-Term Growth

4 days ago - By: The Motley Fool

Why AstraZeneca Stock Bumped Higher Today

4 days ago - By: AstraZeneca

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

4 days ago - By: Zacks Investment Research - Mentions: IRWD ABBV

Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?

4 days ago - By: Zacks Investment Research - Mentions: MRK ADMA EDIT

AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo

4 days ago - By: Zacks Investment Research - Mentions: PFE BMY MRK

PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms

5 days ago - By: Benzinga

FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio

5 days ago - By: The Motley Fool - Mentions: IONQ IBM QBTS MSFT ...

Where Will IonQ Be in 10 Years?

6 days ago - By: Zacks Investment Research - Mentions: JNJ LLY ABBV

AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?

8 days ago - By: Investor's Business Daily - Mentions: JNJ PFE

Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment

12 days ago - By: Zacks Investment Research - Mentions: IRWD ABBV

IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock?

13 days ago - By: Zacks Investment Research

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

14 days ago - By: Zacks Investment Research - Mentions: IRWD ABBV RLAY

IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars

16 days ago - By: AstraZeneca

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

18 days ago - By: Zacks Investment Research - Mentions: PFE NVO MTSR

Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call

18 days ago - By: AstraZeneca

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

18 days ago - By: Zacks Investment Research - Mentions: PH CMI PLNT

Company News for Nov 7, 2025

19 days ago - By: Zacks Investment Research - Mentions: PFE MRK

AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform

19 days ago - By: Zacks Investment Research - Mentions: COP RL MRNA TRIP ...

Earnings Data Deluge

19 days ago - By: Zacks Investment Research - Mentions: COP RL MRNA TRIP ...

Pre-Markets Improve on Big Earnings Morning

19 days ago - By: Investor's Business Daily

AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar

19 days ago - By: Axsome Therapeutics, Inc. - Mentions: AXSM ATXI

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

19 days ago - By: AstraZeneca

AstraZeneca's 9M and Q3 2025 Financial Results

19 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

20 days ago - By: Zacks Investment Research - Mentions: NVO LLY AMGN

Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

21 days ago - By: Stocktwits - Mentions: LLY NVO PFE

Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs

21 days ago - By: Zacks Investment Research - Mentions: PFE NVO MTSR

Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools

25 days ago - By: Zacks Investment Research - Mentions: JNJ BDTX

Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?

25 days ago - By: Zacks Investment Research - Mentions: PFE NVO MTSR

Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?

26 days ago - By: Zacks Investment Research - Mentions: NVS BIIB IONS

ASTRAZENECA PLC-SPONS ADR (AZN) Stock News